Estimating the effectiveness of tetanus-diphtheria-acellular pertussis vaccine (Tdap) for preventing pertussis: Evidence of rapidly waning immunity and difference in effectiveness by Tdap brand

Journal of Infectious Diseases

Volumn 210, Issue 6, 2014, Pages 942-953

  Koepke, Ruth ^a,b   Eickhoff, Jens C ^b   Ayele, Roman A ^a,b,c   Petit, Ashley B ^a,b   Schauer, Stephanie L ^a   Hopfensperger, Daniel J ^a   Conway, James H ^b   Davis, Jeffrey P ^a  

^a WISCONSIN DIVISION OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c Food Science and Human Nutrition   (United States)

Author keywords

Bordetella pertussis; Epidemiology; Immunization information systems; Tdap (tetanus diphtheria acellular pertussis) vaccine; Vaccine effectiveness

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE;

ADOLESCENT; BACTERIAL IMMUNITY; CHILD; CHILDHOOD; COHORT ANALYSIS; CONFERENCE PAPER; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; EPIDEMIC; EPIDEMIOLOGICAL DATA; FEMALE; HUMAN; INCIDENCE RATE RATIO; MAJOR CLINICAL STUDY; MALE; PERTUSSIS; POISSON DISTRIBUTION; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; UNITED STATES; VACCINATION; VACCINE EFFECTIVENESS;

BORDETELLA PERTUSSIS; EPIDEMIOLOGY; IMMUNIZATION INFORMATION SYSTEMS; TDAP (TETANUS-DIPHTHERIA-ACELLULAR PERTUSSIS) VACCINE; VACCINE EFFECTIVENESS;

ADOLESCENT; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; DISEASE OUTBREAKS; HUMANS; INCIDENCE; REGISTRIES; TREATMENT OUTCOME; WHOOPING COUGH; WISCONSIN;

EID: 84907325843     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu322     Document Type: Conference Paper

References (49)

1. Centers for Disease Control and Prevention. U.S. vaccination coverage reported via the National Immunization Survey (NIS). http://www.cdc.gov/ vaccines/imz-managers/coverage/nis/child/index.html. Accessed 18 November 2013.
2. Clark TA. Changing pertussis epidemiology: everything old is new again. J Infect Dis 2014; 209:978-81.
3. Centers for Disease Control and Prevention. Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997; 46:1-25.
4. Centers for Disease Control and Prevention. Recommended childhood immunization schedule-United States, 1997. MMWR Morb Mortal Wkly Rep 1997; 46:35-40.
5. Cherry JD. Epidemic pertussis in 2012-the resurgence of a vaccinepreventable disease. N Engl J Med 2012; 367:785-7.
6. Burns DL, Meade BD, Messionnier NE. Pertussis resurgence: perspectives from the working group meeting on pertussis on the causes, possible paths forward, and gaps in our knowledge. J Infect Dis 2014; 209 (suppl 1):S32-5.
7. Clark TA, Messonnier NE, Hadler SC. Pertussis control: time for something new? Trends Microbiol 2012; 20:211-3.
8. Klein NP, Bartlett J, Fireman B, Rowhani-Rahbar A, Baxter R. Comparative effectiveness of acellular versus whole-cell pertussis vaccines in teenagers. Pediatrics 2013; 131:e1716-22.
9. Liko J, Robison SG, Cieslak PR. Priming with whole-cell versus acellular pertussis vaccine. N Engl J Med 2013; 368:581-2.
10. Sheridan SL,Ware RS, Grimwood K, Lambert SB. Number and order of whole cell pertussis vaccines in infancy and disease protection. JAMA 2012; 308:454-6.
11. Klein NP, Bartlett J, Rowhani-Rahbar A, Fireman B, Baxter R. Waning protection after fifth dose of acellular pertussis vaccine in children. N Engl J Med 2012; 367:1012-9.
12. Misegades LK, Winter K, Harriman K, et al. Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010. JAMA 2012; 308:2126-32.
13. Tartof SY, Lewis M, Kenyon C, et al.Waning immunity to pertussis following 5 doses of DTaP. Pediatrics 2013; 131:e1047-52.
14. Plotkin SA. Complex correlates of protection after vaccination. Clin Infect Dis 2013; 56:1458-65.
15. Broder KR, Cortese MM, Iskander JK, et al. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55:1-34.
16. Wisconsin Administrative Code. Chapter DHS 144: immunization of students. http://docs.legis.wisconsin.gov/code/admin-code/dhs/110/144/03. Accessed 5 June 2013.
17. Wisconsin Division of Public Health. 2012 annual pertussis surveillance summary. http://www.dhs.wisconsin.gov/immunization/pertussis.htm.Accessed 29 May 2013.
18. Schauer SL, Hopfensperger DJ, Verdon MJ, Maerz TR, Gabor GW, Davis JP. An immunization information system to meet evolving needs during the 2009-2010 Influenza A (H1N1) vaccination campaign. Disaster Med Public Health Prep 2012; 6:402-7.
19. Schauer SL, Maerz TR, Hurie MB, Gabor GW, Flynn JM, Davis JP. The use of an immunization information system to establish baseline childhood immunization rates and measure contract objectives. J Public Health Manag Pract 2009; 15:E6-12.
20. Schauer SL, Maerz TR, Verdon MJ, Hopfensperger DJ, Davis JP. The Wisconsin Immunization Registry experience: comparing real-time and batched file submissions from health care providers. WMJ 2014; 113:102-6.
21. Centers for Medicare and MediCaid Services. Electronic health records incentive programs-meaningful use. http://www.cms.gov/Regulationsand-Guidance/ Legislation/EHRIncentivePrograms/Meaningful-Use.html. Accessed 5 June 2013.
22. Centers for Disease Control and Prevention. Manual for the surveillance of vaccine-preventable diseases. Atlanta, GA: Centers for Disease Control and Prevention, 2012.
23. US Census Bureau. Population and housing unit estimates, 2012 state population estimates by age, sex, and Hispanic origin. http://www.census.gov/ popest/data/state/asrh/2012/index.html. Accessed 17 June 2013.
24. Wisconsin Department of Health Services. Division of Public Health-Regional Offices. http://www.dhs.wisconsin.gov/localhealth/counties/ regional.htm. Accessed 25 November 2013.
25. Schafer JL. Multiple imputation: a primer. Stat Methods Med Res 1999; 8:3-15.
26. Rubin D. Multiple imputation for nonresponse in surveys. New York: Wiley & Sons, 1987.
27. Baxter R, Bartlett J, Rowhani-Rahbar A, Fireman B, Klein NP. Effectiveness of pertussis vaccines for adolescents and adults: case-control study. BMJ 2013; 347:f4249.
28. Rodgers L, Martin SW, Cohn A, et al. Epidemiologic and laboratory features of a large outbreak of pertussis-like illnesses associated with cocirculating Bordetella holmesii and Bordetella pertussis-Ohio, 2010-2011. Clin Infect Dis 2013; 56:322-31.
29. Wei SC, Tatti K, Cushing K, et al. Effectiveness of adolescent and adult tetanus, reduced-dose diphtheria, and acellular pertussis vaccine against pertussis. Clin Infect Dis 2010; 51:315-21.
30. Acosta A, Debolt C, Tasslimi A, et al. Vaccine Effectiveness and Duration of Protection of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis among Adolescents, Washington State, 2012 IDWeek. San Francisco, CA, 2013. https://idsa.confex.com/idsa/2013/webprogram/Paper41599.html.
31. Cherry JD. Why do pertussis vaccines fail? Pediatrics 2012; 129:968-70.
32. Cherry JD, Heininger U, Richards DM, et al. Antibody response patterns to Bordetella pertussis antigens in vaccinated (primed) and unvaccinated (unprimed) young children with pertussis. Clin Vaccine Immunol 2010; 17:741-7.
33. Carollo M, Pandolfi E, Tozzi AE, Buisman AM, Mascart F, Ausiello CM. Humoral and B-cell memory responses in children five years after pertussis acellular vaccine priming. Vaccine 2014; 32:2093-9.
34. Cherry JD. Pertussis: challenges today and for the future. PLoS Pathog 2013; 9:e1003418.
35. Pawloski LC, Queenan AM, Cassiday PK, et al. Prevalence and molecular characterization of pertactin-deficient bordetella pertussis in the United States. Clin Vaccine Immunol 2014; 21:119-25.
36. Queenan AM, Cassiday PK, Evangelista A. Pertactin-negative variants of Bordetella pertussis in the United States. N Engl J Med 2013; 368:583-4.
37. Quinlan T, Musser KA, Currenti SA, Zansky SM, Halse TA. Pertactinnegative variants of Bordetella pertussis in New York State: A retrospective analysis, 2004-2013. Mol Cell Probes 2014; 28:138-40.
38. American Immunization Registry Association. Management of Moved or Gone Elsewhere (MOGE) status and other patient designations in immunization information systems. Atlanta, GA: Modeling of Immunization Registry Operations Workgroup, 2005.
39. Gowda C, Dong S, Potter RC, Dombkowski KJ, Stokley S, Dempsey AF. A systematic evaluation of different methods for calculating adolescent vaccination levels using immunization information system data. Public Health Rep 2013; 128:489-97.
40. Centers for Disease Control and Prevention. National and state vaccination coverage among adolescents aged 13-17 years-United States, 2012. MMWR Morb Mortal Wkly Rep 2013; 62:685-93.
41. Bartholomew M, Koepke R, Aydkio Ayele R, et al. Widespread Bordetella parapertussis infections-Wisconsin, October 2011-May 2012. Presented at: IDWeek 2013, San Francisco, CA, 2013.
42. Bergfors E, Trollfors B, Taranger J, Lagergard T, Sundh V, Zackrisson G. Parapertussis and pertussis: differences and similarities in incidence, clinical course, and antibody responses. Int J Infect Dis 1999; 3:140-6.
43. Heininger U, Stehr K, Schmitt-Grohe S, et al. Clinical characteristics of illness caused by Bordetella parapertussis compared with illness caused by Bordetella pertussis. Pediatr Infect Dis J 1994; 13:306-9.
44. Cherry JD, Seaton BL. Patterns of Bordetella parapertussis respiratory illnesses: 2008-2010. Clin Infect Dis 2012; 54:534-7.
45. Centers for Disease Control and Prevention. Pertussis vaccination: acellular pertussis vaccine for the fourth and fifth doses of the DTP series update to supplementary ACIP statement. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1992; 41:1-5.
46. Centers for Disease Control and Prevention. Update on the supply of tetanus and diphtheria toxoids and of diphtheria and tetanus toxoids and acellular pertussis vaccine. MMWR Morb Mortal Wkly Rep 2001; 50:189-90.
47. Centers for Disease Control and Prevention. Food and Drug Administration approval of a fifth acellular pertussis vaccine for use among infants and young children-United States, 2002. MMWR Morb Mortal Wkly Rep 2002; 51:574.
48. U.S. Food and Drug Administration. Vaccines Licensed for Immunization and Distribution in the US with Supporting Documents, Vaccines, Blood & Biologics. http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ ucm093830.htm. Accessed 19 November 2013.
49. Centers for Disease Control and Prevention. FDA licensure of diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis B (recombinant), and poliovirus vaccine combined, (PEDIARIX) for use in infants. MMWR Morb Mortal Wkly Rep 2003; 52:203-4.